Skip to main content

Lipo-Group Research Constellation (LGRC)

The final goal of our research activity is the discovery of biomarkers and therapeutic targets for the diagnosis and treatment of cardiometabolic diseases by increasing the knowledge on lipoprotein, lipid, and carbohydrate metabolism.

Cardiometabolic diseases (atherosclerotic cardiovascular disease, diabetes mellitus type II, and non-alcoholic fatty liver disease) are the first cause of mortality and hospitalization worldwide. Epidemiological studies have shown the complexity of cardiometabolic diseases identifying a large number of risk factors.

The liver is a fundamental organ for the regulation of lipoprotein, lipid, and carbohydrate metabolism, being the centre of the physiologic processes that maintain carbohydrate and lipid homeostasis.

The Lipo-Group Research Constellation (LGRC), led by Paolo Parini,  Mats Eriksson and Uwe Tietge, merges the efforts and background from various medical specialties (internal medicine, hepatology, gastroenterology, and endocrinology) with the science from genetics, clinical biochemistry, and molecular biology.

The multi-disciplinary expertise and the deep knowledge of human physiology allow LGRC to drive translational pre-clinical and clinical research activities and to integrated the results into models and hypotheses that are translatable to human condition.

Examples of research projects within LGRC

HUMAN (Health and the Understanding of Metabolism, Aging and Nutrition, is a consortium with a EU-funded research project that started in October 2013. HUMAN aims to study the function of genetic risk variant associated to metabolic diseases by employing a unique translational model of human glucose and lipid metabolism: mouse with humanised liver and pancreas. Paolo Parini is the coordinator of HUMAN, and with several member of the LGRC actively contribute with a research activity aimed to: 1) characterize the metabolic phenotype of the humanized mice produced within the consortium, specifically by determining whether the liver humanized mouse model recreates the metabolic characteristics of a human liver and by characterizing changes in clinical metabolic parameters of disease and aging; 2) investigate sex related differences in hepatic lipid and lipoprotein metabolism of the liver humanized mice by repopulation of male or female animals with hepatocytes from disease-free women or men; 3) investigate the humanized phenotype of liver-targeted pharmacology, using the oxysterol receptor LXR as a model system; 4) use CRISPR/Cas9 to genetically modify iPSCs carrying risk/protective alleles.

Professor Uwe Tietge is the newest member of LGRC and brings an additional layer of knowledge. The general theme of his research is to elucidate the molecular regulation of cardiometabolic disease with a focus on (chole)sterol metabolism. As other research projects within LGRC this work is multidisciplinary, extending beyond the physiology of metabolism to a number of relevant biological processes such as inflammation, regeneration and ageing as well as their related outcomes such as atherosclerosis.  Central to Tietge’s research are the relevance for human disease and the in vivo aspect, mostly comprising characterization of physiological processes with the help of mouse models. This translational work tests concepts generated in animal models also in human patients or take a vice versa approach to understand the mechanistic basis of clinical observations with the help of animal or cell culture models. Specifically, the following topics are the current focus his work: 1) HDL function and regulation of reverse cholesterol transport; 2) Epigenetic programming of metabolic and cardiovascular health; 3) Impact of the intestinal microbiota on inflammation, bile acid metabolism and cardiometabolic disease including the use of germ-free models.

LGRC also offers a unique competence and technological platform to drive studies for: a) pharmacological target validation, b) evaluation of lipid and glucose metabolism, c) detailed characterization of lipoprotein composition, structure and functions.

Please contact us for more information and possible future collaborations.

Research group leaders

Paolo Parini

Professor/senior physician
H7 Department of Medicine, Huddinge

Mats Eriksson

Adjunct professor
H7 Department of Medicine, Huddinge

Uwe Tietge

Professor/clinical chemist
H5 Department of Laboratory Medicine

Germán Camejo

Affiliated to research
H5 Department of Laboratory Medicine

Paolo Garagnani

Affiliated to research
H5 Department of Laboratory Medicine

Tomas Jakobsson

Affiliated to research
H5 Department of Laboratory Medicine

Karin Littman

PhD Student
H5 Department of Laboratory Medicine

Mirko Minniti

PhD student
H5 Department of Laboratory Medicine

Maria Olin

Biomedical scientist
H5 Department of Laboratory Medicine

Matteo Pedrelli

Research coordinator
H5 Department of Laboratory Medicine

Camilla Pramfalk

Lecturer, adjunct
H5 Department of Laboratory Medicine

Knut Steffensen

Leave of absence
H5.Klin Kemi
H5 Department of Laboratory Medicine
H5 Department of Laboratory Medicine

Lise-Lotte Vedin

International coordinator
UF Central Administration

Research techniques

CRISPR Cas9 gene editing, Lipoproteins isolation and characterization (i.e. D2O-sucrose and KBr gradient ultracentrifugation, native and denatured polyacrylamide gel electrophoresis, size exclusion chromatography, serum and HDL cholesterol efflux capacity measurement, lipoprotein binding to arterial proteoglycans), extraction and quantification of lipids and glycogen in cells and tissues, RNA-DNA extraction and purification, enzymatic and ELISA assays, gene expression, protein expression, cloning, mutagenesis, cell culture, transfections.

Work with animal models: quantification of macrophagic reverse cholesterol transport (RCT) in- vivo, glucose and insulin tolerance test, evaluation of atherosclerosis development in the aorta, mouse genotyping, tissue and organ collection, gavage, tail vein injection

External funding

EU Fp7 HUMAN (, Swedish Heart-Lung foundation, AstraZeneca, Swedish Research Council, ALF, SSMF, Moderna

Teaching assignments

BMA undergraduate program, postgraduate courses, medical program, bachelor programs in Biomedicine and Nutrition

Selected publications

New insights from liver-humanized mice on cholesterol lipoprotein metabolism and LXR-agonist pharmacodynamics in humans.
Minniti ME, Pedrelli M, Vedin LL, Delbès AS, Denis RGP, Öörni K, et al
Hepatology 2019 Nov;():

Inhibiting Cholesterol Absorption During Lactation Programs Future Intestinal Absorption of Cholesterol in Adult Mice.
Dimova LG, de Boer JF, Plantinga J, Plösch T, Hoekstra M, Verkade HJ, et al
Gastroenterology 2017 08;153(2):382-385.e3

Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice.
Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJ
Gastroenterology 2011 Mar;140(3):1043-51

Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism.
Pramfalk C, Larsson L, Härdfeldt J, Eriksson M, Parini P
Biochim. Biophys. Acta 2016 Jan;1861(1):51-59

Lipids around the Clock: Focus on Circadian Rhythms and Lipid Metabolism.
Gnocchi D, Pedrelli M, Hurt-Camejo E, Parini P
Biology (Basel) 2015 Feb;4(1):104-32

The oxysterol receptor LXRβ protects against DSS- and TNBS-induced colitis in mice.
Jakobsson T, Vedin LL, Hassan T, Venteclef N, Greco D, D'Amato M, et al
Mucosal Immunol 2014 Nov;7(6):1416-28

Deactivating Fatty Acids: Acyl-CoA Thioesterase-Mediated Control of Lipid Metabolism.
Tillander V, Alexson SEH, Cohen DE
Trends Endocrinol. Metab. 2017 07;28(7):473-484